Physician profile
Karan Seegobin
NPI 1225482888
$2,295.74
in general payments reported to CMS, 2019-2025
19 companies · $94.49 in 2025
The $94.49 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $349 · 2021: $633 · 2022: $871 · 2024: $41.81 · 2025: $94.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $136.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $480.47 | 2019-2022 | |
| Seagen INC. | $426.40 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $274.60 | 2021 | |
| Genentech USA, INC. | $248.36 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $153.21 | 2020-2022 | |
| Eisai INC. | $142.97 | 2020-2022 | |
| Apellis Pharmaceuticals, INC. | $117.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.19 | 2022 | |
| Janssen Biotech, INC. | $71.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Pfizer INC. | $51.52 | 2024-2025 | |
| Kyowa Kirin, INC. | $40.97 | 2020-2021 | |
| Puma Biotechnology, INC. | $23.26 | 2020 | |
| Astellas Pharma Global Development | $22.87 | 2020 | |
| Jazz Pharmaceuticals INC. | $18.39 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $17.45 | 2019 | |
| Omeros Corporation | $17.02 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.29 | 2024 | Reblozyl |
| Abbvie INC. | $14.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Seegobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.